SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology Inc. is seeing significant market interest as investors react to a confirmed partnership with AMD for AI compute infrastructure and aggressive workforce realignment strategies aimed at driving future growth. Community sentiment is mixed but largely bullish, with many focusing on the stock's potential for institutional accumulation and its pivot toward high-margin AI data center services.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as traders react to a significant workforce reduction aimed at streamlining operations amidst record-breaking trading volumes across its equity, options, and prediction market platforms. The community is actively debating whether this efficiency play signals long-term growth or cooling momentum, while many are focused on key price levels and bullish sentiment regarding the company's broader push into AI-driven trading tools and international expansion.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging as investors react to its upcoming inclusion in the Nasdaq-100 and the completed acquisition of Eigen AI, which strengthens its inference optimization capabilities. The community is actively debating the stock's long-term potential as a hyperscaler-style AI infrastructure winner versus concerns regarding its debt load and broader sector leverage.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investors cheer positive data for the subcutaneous version of its flagship MS treatment, which supports a streamlined dosing schedule and bolsters long-term growth prospects. The community is buzzing with speculation that the company's improved clinical profile and expanded market opportunity make it a prime candidate for a significant buyout.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing heightened volatility and intense social media debate as investors weigh the impact of acquisition rumors, potential M&A strategy shifts, and recent downward price action against its underlying subscriber growth. The community remains deeply divided, with many expressing frustration over management's capital allocation and content direction while others argue the stock is fundamentally undervalued at current levels.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market participants are fixated on the Federal Reserve's latest interest rate decision, with the community intensely debating whether the new leadership will signal a pivot or continue a restrictive stance. The sentiment is characterized by high volatility and caution, as traders scrutinize economic data and political headlines for clues on future inflation policy.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Investors are closely monitoring small-cap performance and sectoral rotation ahead of the upcoming Federal Reserve policy decision and key inflation reports, with community sentiment divided between bullish outlooks on small-cap breadth and concerns over potential downside from hawkish monetary policy. Active discussions highlight high put-to-call ratios on IWM as traders hedge against rate-sensitive volatility while debating the broader market's ability to sustain current levels without tech-sector leadership.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors position for significant upcoming catalysts, including Phase 3 data readouts and potential M&A interest. The community is actively debating the company's clinical pipeline milestones and the strategic implications of management's participation at major upcoming investor conferences.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor a high-stakes legal battle with Nippon Shinyaku, which many in the community view as a critical hurdle to clear ahead of the anticipated August PDUFA date for deramiocel. While some are concerned about the procedural delays, others are actively accumulating shares and highlighting the company's strong clinical data and potential for independent commercialization as primary reasons for their bullish outlook.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is under intense scrutiny as investors grapple with slowing enterprise IT spending and fears that generative AI could disrupt its traditional consulting model. While the company faces pressure from recent institutional downgrades, market attention is focused on whether its upcoming earnings can signal a turnaround by proving that AI implementation, rather than just automation, is driving sustainable revenue growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$JAZZ and $ABCL enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors. https://notreload.xyz/xy/jazz-abcellera-sign-876m-deal-for-t-cell-engagers/

Stonk Trades

Ckkung71

Jazz Pharmaceuticals and AbCellera enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors.

NOTRELOAD AI

Jazz & AbCellera Sign $876M Deal for T-Cell Engagers

StockTwits Web

Jazz Pharmaceuticals plc

AbCellera Biologics Inc

 enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors. 

@notreload_ai That is some great talent teaming up, Baker Bros and Bruce Cozadd

Justin

StockTwits For Android 

 That is some great talent teaming up, Baker Bros and Bruce Cozadd

Bret

@notreload_ai it’s worth up to $4.1b. Each program is worth ~$820M in milestone payments plus all the royalties. They have up to 5 programs.

StockTwits for iOS

 it’s worth up to $4.1b. Each program is worth ~$820M in milestone payments plus all the royalties. They have up to 5 programs.